SYDNEY, Sept. 9,
2022 /PRNewswire/ -- Kazia Therapeutics
Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug
development company, is pleased to announce that CEO, Dr
James Garner, will be presenting at
the upcoming 24th Annual Global Investment Conference,
held in New York, NY, from 12 –
14 September 2022.
Dr Garner's presentation will review three positive data
read-outs that Kazia has reported so far in 2022 and will look
ahead to some key developments that are anticipated over coming
months.
Representatives of the Kazia management team will be available
to conduct one-on-one meetings with institutional investors through
the conference. To register for the conference, please visit:
https://hcwevents.com/annualconference/.
For More Information, Please Contact:-
In the United States:
|
In Australia:
|
Joe Green
|
Jane Lowe
|
Edison Investor
Relations
|
IR
Department
|
jgreen@edisongroup.com
|
jane.lowe@irdepartment.com.au
|
Phone: +1
646-653-7030
|
Phone: +61 411 117
774
|
About Kazia Therapeutics
Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an
oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of
the PI3K / Akt / mTOR pathway, which is being developed to treat
glioblastoma, the most common and most aggressive form of primary
brain cancer in adults. Licensed from Genentech in late 2016,
paxalisib commenced recruitment to GBM AGILE, a pivotal study in
glioblastoma, in January 2021. Seven
additional studies are active in various forms of brain cancer.
Paxalisib was granted Orphan Drug Designation for glioblastoma by
the US FDA in February 2018, and Fast
Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted
Rare Pediatric Disease Designation and Orphan Designation by the US
FDA for DIPG in August 2020, and for
AT/RT in June 2022.
Kazia is also developing EVT801, a small-molecule inhibitor of
VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided
compelling evidence of synergy with immuno-oncology agents. A phase
I study commenced recruitment in November
2021.
For more information, please visit www.kaziatherapeutics.com or
follow us on Twitter @KaziaTx.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kazia-therapeutics-to-present-at-hc-wainwright-24th-annual-global-investment-conference-301620757.html
SOURCE Kazia Therapeutics Limited